证券代码：301122 证券简称：采纳股份 公告编号：2025-089 采纳科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险 的前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含 超募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内， 资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的相关公告。 ...

Core Points - New Oriental Education Technology Group announced a cash dividend of $0.06 per share for the fiscal year ending May 31, 2026 [1] - The ex-dividend date is set for November 17, 2025, with the record date on November 18, 2025, and the payment date on December 2, 2025 [1] - The dividend will be paid in US dollars without withholding tax [1] - The company's board of directors has adopted a share repurchase plan, although specific details have not been disclosed [1] - The board includes prominent members such as Yu Minhong, Zhou Chenggang, and independent directors Li Yanhong, Li Tingbin, and Zhuge Yue [1]

Group 1 - The company has announced a cash dividend and share buyback plan as part of its shareholder return program approved in July 2025 for the fiscal year 2026 [1] - The cash dividend will be $0.12 per ordinary share or $1.2 per American Depositary Share (ADS), to be paid in two installments [1] - The total cash dividend amount expected to be distributed in two installments is approximately $190 million [1] Group 2 - To qualify for the first dividend payment, ordinary shareholders must submit all valid share transfer documents by November 18, 2025 [2] - The company plans to repurchase up to $300 million of its ADS or ordinary shares within the next 12 months [2] - The repurchase may occur through various methods, including open market purchases and private negotiations, depending on market conditions and applicable laws [2]

Core Points - New Oriental Education & Technology Group Inc. announced a cash dividend and share repurchase plan as part of its shareholder return program for the fiscal year 2026 [1][2] - The cash dividend will be $0.12 per ordinary share or $1.2 per American Depositary Share, distributed in two installments [1] - The first installment of the dividend is expected to be paid on December 2, 2025, and the second installment approximately six months later [1] Dividend Details - The cash dividend will be paid in two phases: $0.06 per ordinary share for the first phase and the same amount for the second phase [1] - The record date for the first phase of the dividend is set for November 18, 2025 [1] Share Repurchase Plan - The company plans to repurchase up to $300 million of its American Depositary Shares or ordinary shares within the next 12 months [2] - The repurchase may occur through various methods, including open market purchases and private negotiations, depending on market conditions [2] - The funding for the repurchase is expected to come from the company's existing cash balance [2]

Group 1 - The company New Oriental-S (09901) announced a cash dividend and share repurchase plan as part of its three-year shareholder return plan approved in July 2025 for the fiscal year 2026 [1] - The cash dividend will be $0.12 per ordinary share or $1.2 per American Depositary Share (ADS), to be paid in two installments [1] - The total cash dividend amount expected to be distributed in two installments is approximately $190 million [1] Group 2 - To qualify for the first dividend payment, ordinary shareholders must submit all valid share transfer documents by November 18, 2025, at 4:30 PM [2] - The company plans to repurchase up to $300 million of its ADS or ordinary shares within the next 12 months, depending on market conditions and applicable laws [2] - The repurchase funds are expected to come from the company's existing cash balance [2]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 246 million yuan, representing a year-on-year decrease of 15.86% [1] - The net profit attributable to shareholders of the listed company was 8.25 million yuan, down 85.64% year-on-year [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 1.88 million yuan [1] - Basic earnings per share were reported at 0.07 yuan [1]

Core Viewpoint - The company reported a decline in revenue and a net loss for the third quarter of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The operating revenue for the third quarter was 87.39 million, representing a year-on-year decrease of 10.54% [1] - The net profit attributable to shareholders was a loss of 1.12 million [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of 4.36 million [1]

Group 1 - The core viewpoint of the news is that Cai Na Co., Ltd. reported a significant decline in its third-quarter performance for 2025, with revenue and net profit both decreasing sharply compared to the previous year [1] Group 2 - For the first three quarters of 2025, the company's revenue was approximately 246 million yuan, representing a year-on-year decrease of 15.86% [1] - The net profit attributable to shareholders was about 8.25 million yuan, which is a year-on-year decrease of 85.64% [1] - The basic earnings per share were 0.07 yuan, reflecting a year-on-year decrease of 85.11% [1] Group 3 - As of the report date, Cai Na Co., Ltd. had a market capitalization of 3.2 billion yuan [2]

Financial Performance - The company's revenue for Q3 2025 was ¥87,393,800.82, representing a decrease of 10.54% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥1,119,485.00, a decline of 104.62% year-on-year[5] - Total operating revenue for Q3 2025 was CNY 245,772,123.41, a decrease of 15.8% compared to CNY 292,116,185.53 in the same period last year[25] - Net profit for the period was CNY 7,325,822.33, a significant decline of 87.3% compared to CNY 57,452,000.48 in the previous year[26] - The company reported a decrease in gross profit margin, with operating profit dropping to CNY 8,411,563.73 from CNY 62,292,887.26 year-over-year[26] Cash Flow - The net cash flow from operating activities decreased by 60.50% to ¥33,682,759.82 year-to-date[12] - Operating cash flow for the current period is ¥33,682,759.82, a decrease of 60.5% compared to ¥85,277,615.90 in the previous period[28] - Net cash flow from financing activities is -¥28,657,310.20, an improvement from -¥49,043,263.20 in the previous period[29] - Cash inflow from financing activities totals ¥5,733,955.69, compared to ¥1,038,081.76 in the previous period[29] - The ending balance of cash and cash equivalents is ¥361,201,466.73, an increase from ¥275,633,116.58 in the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,930,383,529.43, down 2.55% from the end of the previous year[5] - Total non-current assets increased to CNY 935,596,428.31, up from CNY 846,590,930.24 year-over-year[22] - Total liabilities decreased to CNY 134,847,556.11 from CNY 166,483,138.90 in the previous year[23] - The company’s total assets were CNY 1,930,383,529.43, down from CNY 1,980,925,047.43 year-over-year[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,731[14] - The largest shareholder, Lu Jun, holds 28.29% of shares, totaling 34,580,000 shares[14] - The total number of restricted shares held by major shareholders remains unchanged at 78,000,000 shares[17] - The company has not identified any related party transactions among the top shareholders[15] Operational Challenges - The company is currently facing an FDA import warning affecting its subsidiary, Jiangsu Caina Medical Technology Co., Ltd., which may significantly impact future revenue and profits[19] - The company is actively communicating with the FDA to resolve the import warning issue but cannot predict the timeline for resolution[19] - Inventory increased by 30.60% to ¥96,536,076.93, primarily due to slow shipments influenced by overseas market conditions[9] - The company has not disclosed any new product developments or market expansions in the current report[18] Expenses - The company's management expenses rose by 55.81% to ¥37,734,189.88, mainly due to increased depreciation of new factory assets[10] - Investment income decreased by 30.53% to ¥9,623,896.44, attributed to reduced cash management returns[10] - The company reported a significant increase in tax and additional charges by 86.33% to ¥4,566,516.93, mainly due to property tax on newly added factory assets[10] - Research and development expenses were CNY 16,446,738.78, down 13.4% from CNY 18,993,814.45 in the previous year[25]

Core Viewpoint - China Jinshi (01380) announced a proposal for a share award plan aimed at incentivizing qualified participants to contribute to the company and attract high-quality talent [1] Group 1: Share Award Plan - The share award plan is designed to align the interests of selected participants with those of the company and its shareholders, thereby motivating participants to enhance performance [1] - The company proposes to grant 23.3 million shares as rewards to Executive Director and CEO Chen Tianxing, contingent upon approval from independent shareholders at a special general meeting [1]